EZH2 and neoplasm: Loss of Ezh2 or inhibition of its enzymatic activity with small molecules in both mouse and human hematopoietic stem and progenitor cells enhanced NK cell expansion and cytotoxicity against tumor cells through upregulation of CD122 and NKG2D (Table 1) (70).